Showing results (1-10 of 296) with videos related to
Sort By:
Pageof 30
Nephron|September 1, 2016
Long Term Treatment with Enzyme Replacement Therapy in Patients with Fabry DiseaseDaniel Oder, Peter Nordbeck, Christoph WannerCardiovascular Diagnosis and Therapy|May 10, 2021
Contemporary therapeutics and new drug developments for treatment of Fabry disease: a narrative reviewDaniel Oder, Jonas Müntze, Peter NordbeckBMC Medical Genetics|July 20, 2016
Case report of a 45-year old female Fabry disease patient carrying two alpha-galactosidase A gene mutation allelesDaniel Oder, Dorothee Vergho, Georg Ertl, et al.Deutsche Medizinische Wochenschrift (1946)|March 23, 2017
[The Fabry's Disease Cardiomyopathy as Differential Diagnosis of Acute Coronary Syndrome]Daniel Oder, Stefan Störk, Christoph Wanner, et al.BMJ Open|April 10, 2016
Organ manifestations and long-term outcome of Fabry disease in patients with the GLA haplotype D313YDaniel Oder, Nurcan Üçeyler, Dan Liu, et al.Clinical Pharmacology and Therapeutics|July 13, 2017
Lucerastat, an Iminosugar for Substrate Reduction Therapy: Tolerability, Pharmacodynamics, and Pharmacokinetics in Patients With Fabry Disease on Enzyme ReplacementNicolas Guérard, Daniel Oder, Peter Nordbeck, et al.Journal of Cardiac Failure|November 29, 2016
Echocardiographic Determinants of One-Year All-Cause Mortality in Patients With Chronic Heart Failure Complicated by Significant Functional Tricuspid RegurgitationKai Hu, Dan Liu, Stefan Störk, et al.Journal of Thoracic Disease|September 21, 2018
Value of cardiac biomarker measurement in the differential diagnosis of infiltrative cardiomyopathy patients with preserved left ventricular systolic functionKai Hu, Dan Liu, Tim Salinger, et al.Plos One|November 22, 2017
Cardiac and renal dysfunction is associated with progressive hearing loss in patients with Fabry diseaseMaria Köping, Wafaa Shehata-Dieler, Mario Cebulla, et al.Clinical Pharmacology and Therapeutics|December 4, 2018
Oral Chaperone Therapy Migalastat for Treating Fabry Disease: Enzymatic Response and Serum Biomarker Changes After 1 YearJonas Müntze, Daniel Gensler, Octavian Maniuc, et al.Pageof 30